(Reuters Health) By Lisa Rapaport - The quality of outpatient care hasn't changed much in the U.S. over the past decade despite a variety of local, regional and national efforts to encourage improvements, a study suggests."Overall, the quality of outpatient care has remained largely flat; there

(Reuters) By Reuters Staff - Regeneron Pharmaceuticals Inc and partner Teva Pharmaceutical Industries Ltd said the U.S. health regulator placed a clinical hold on a mid-stage study of their experimental drug for chronic lower back pain.The Food and Drug Administration's (FDA) decision followed a

NEW YORK (Reuters Health)By Marilynn Larkin - Clinicians can safely observe patients with a first episode of uncomplicated diverticulitis and omit the routine use of antibiotics, researchers in the Netherlands report."Colonic diverticular disease is a common condition in Western society which has a

(Reuters) By Reuters Staff - Danish drugmaker H Lundbeck A/S said its late-stage study testing an experimental drug to treat mild to moderate Alzheimer's disease failed.The company said both doses of its drug idalopirdine failed to improve symptoms of the disease measured on the Alzheimer's

LONDON (Reuters) By Ben Hirschler - Emerging markets have lost their luster for Big Pharma making drug firms ever more dependent on the United States for growth just as American anger over high medicine prices is building.A few years ago, the developing world was seen as a savior as patent after pat

LONDON (Reuters) By Reuters Staff - A new drug to treat a rare inherited bone disorder that was developed by Alexion Pharmaceuticals and could cost up to 1.5 million pounds ($2 million) a year per patient has been cleared for limited use by Britain's health cost watchdog.The National Institute f